Maze Therapeutics appoints two new directors to board
Biotech firm Maze Therapeutics adds two independent directors to its board, expanding oversight amid ongoing pipeline development.
Maze Therapeutics Inc. said on Wednesday it has appointed two new independent directors to its board, bringing the total number of directors to nine.
The company named Diana Brainard and David Meeker as new board members, effective immediately. Brainard is the chief executive officer of Gilead Sciences’ hepatitis B and HIV programs, while Meeker serves as president and CEO of Flagship Pioneering’s Omega Therapeutics.
The appointments follow recent leadership changes at Maze Therapeutics, including the departure of former CEO Jason Coloma in August. The biotech company, which focuses on rare disease treatments, has also expanded its pipeline with multiple investigational programs in recent months.
A company spokesperson said the additions strengthen the board’s expertise in drug development and commercial strategy. Maze Therapeutics’ shares were trading 1.2% higher in pre-market activity following the announcement.
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →